Summit Therapeutics Plunges 27% as Cancer Drug Misses Early Trial Goal

A high-stakes bet on an early win for its lung cancer drug ivonescimab backfired on Summit Therapeutics, raising questions about its strategy just months ahead of a final data readout.

Summit Therapeutics Inc. (NASDAQ:SMMT) shares plummeted nearly 27% after an interim analysis of its pivotal HARMONi-3 trial for the lung cancer drug ivonescimab failed to meet the high bar for early success, complicating its path to challenge Merck’s blockbuster Keytruda.

The disclosure amounts to a “self-inflicted narrative complication,” leaving some investors to wonder why Summit created a situation that offered “more risk than regulatory upside” in the first place, Stifel analyst Dara Azar wrote in a note.

The independent data board for the Phase 3 trial in squamous non-small cell lung cancer (NSCLC) recommended the study continue as planned. Summit conceded the interim analysis required clearing “a meaningfully higher bar” to enable early regulatory discussions, with a final analysis now slated for the second half of 2026.

The setback puts intense pressure on the final 2026 readout, which will determine the fate of a drug positioned to disrupt the multi-billion dollar lung cancer market dominated by Merck. For investors, it turns the stock into a binary bet on a single upcoming data release.

A Calculated Risk Misfires

Ivonescimab, a bispecific antibody developed with Chinese biotech Akeso (09926.HK), targets both the PD-1 and VEGF pathways. This dual mechanism aims to simultaneously unleash the immune system against cancer and choke off the tumor's blood supply. The HARMONi-3 study is testing the drug against Merck’s Keytruda, the current standard of care, making it a direct challenge to one of oncology's most successful products.

Summit opted for an early look at the data in hopes of accelerating regulatory engagement. However, the failure to achieve a statistically significant result at this stage, while not dooming the trial, has spooked investors who were banking on a clear early victory.

Analysts Divided on Path Forward

The market reaction was swift, but analyst opinion is split. While Stifel’s Azar questioned the company's strategy, JPMorgan analysts maintained an "Overweight" rating on Summit's partner Akeso. They noted the high statistical threshold for the interim analysis made a miss unsurprising and that the final readout in the second half of 2026 still holds a "relatively high probability of success."

This division highlights the complex history of ivonescimab. The drug previously delivered impressive progression-free survival (PFS) data in China-only studies, including outperforming Keytruda in the HARMONi-2 trial. However, a missed overall survival goal in a global trial in May 2025 raised concerns about its effectiveness in more diverse Western populations, a fear rekindled by the latest news.

For Summit, everything now rides on the final data. A positive result could still position ivonescimab as a new standard of care and send the stock soaring. A failure, however, would be a devastating blow, making the second half of 2026 a critical period for the company and its investors.

This article is for informational purposes only and does not constitute investment advice.